GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (NAS:NRXP) » Definitions » Forward Dividend Yield %

NRXP (NRX Pharmaceuticals) Forward Dividend Yield % : 0.00% (As of May. 05, 2025)


View and export this data going back to 2021. Start your Free Trial

What is NRX Pharmaceuticals Forward Dividend Yield %?

As of today (2025-05-05), the Forward Annual Dividend Yield of NRX Pharmaceuticals is 0.00%.

As of today (2025-05-05), the Trailing Annual Dividend Yield of NRX Pharmaceuticals is 0.00%.

NRXP's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.535
* Ranked among companies with meaningful Forward Dividend Yield % only.

NRX Pharmaceuticals's Dividends per Share for the three months ended in Dec. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of NRX Pharmaceuticals's Forward Dividend Yield %

For the Biotechnology subindustry, NRX Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NRX Pharmaceuticals's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NRX Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where NRX Pharmaceuticals's Forward Dividend Yield % falls into.


;
;

NRX Pharmaceuticals Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


NRX Pharmaceuticals  (NAS:NRXP) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


NRX Pharmaceuticals Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of NRX Pharmaceuticals's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


NRX Pharmaceuticals Business Description

Traded in Other Exchanges
Address
1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Executives
Jonathan C Javitt director, 10 percent owner, officer: Chief Scientist 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Richard Clavano Narido officer: Interim CFO 12 HANSEN CT, MORAGA CA 94556
Aaron Gorovitz director 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Chaim Hurvitz director C/O GALMED PHARMACEUTICALS LTD., 8 SHAUL, HAMELECH BLVD, AMOT HAMISHPAT BLDG., TEL AVIV L3 64733
Voorhees Seth Van officer: Chief Financial Officer 12 HARVEY DRIVE, SHORT HILLS NJ 07078
Stephen H Willard director, officer: Chief Executive Officer 1201 ORANGE STREET, SUITE 600, WILMINGTON DE 19801
Daniel C. Javitt 10 percent owner 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Patrick John Flynn director 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Ira S Strassberg officer: Chief Financial Officer C/O CONTINENTAL BUILDING PRODUCTS, 12950 WORLDGATE DRIVE, HERNDON VA 20170
Robert Besthof officer: Chief Comm. & Patient Officer 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Alessandra Daigneault officer: General Counsel & Secretary 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Herbert Raymond Mcmaster director C/O ZOOM VIDEO COMMUNICATIONS, INC., 55 ALMADEN BOULEVARD, 6TH FLOOR, SAN JOSE CA 95113
William Fricker officer: CFO & Treasurer 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Big Rock Partners Sponsor, Llc 10 percent owner 2645 N. FEDERAL HIGHWAY, SUITE 230, DELRAY BEACH FL 33483
Richard Ackerman director, 10 percent owner, officer: President & CEO 2645 N. FEDERAL HIGHWAY, SUITE 230, DELRAY BEACH FL 33483

NRX Pharmaceuticals Headlines

From GuruFocus